Evidence map›Paper›PMID 25893658›Full record

ArticleAIDS and behavior2015

Novel Approaches for Visualizing and Analyzing Dose-Timing Data from Electronic Drug Monitors, or "How the 'Broken Window' Theory Pertains to ART Adherence".

Christopher J Gill, Mary Bachman DeSilva, Davidson H Hamer, Xu Keyi, Ira B Wilson, Lora Sabin

Abstract read
In one paragraph

Article in AIDS and behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Christopher J GillDepartment of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA. cgill@bu.edu.
Mary Bachman DeSilvaDepartment of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA.
Davidson H HamerDepartment of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA.
Xu KeyiDepartment of STDs and Dermatology, Ditan Hospital, Beijing, China.
Ira B WilsonDepartment of Health Services, Policy and Practice, Brown University, Providence, RI, USA.
Lora SabinDepartment of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA.
Center for Global Development · USBeijing Ditan Hospital · CNBoston University · USBrown University · USCenter for Global Health · US

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Improving the diagnosis and treatment of medication adherence problems in HIVK24MH092242 · NIMH · BROWN UNIVERSITY · PI WILSON, IRA B · 2010 to 2014
$937k
co-Trimoxazole in Zambian Infants (TZI)K23AI062208 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILL, CHRISTOPHER J · 2004 to 2007
$509k
NIAID NIH HHS K23 AI062208NIAID NIH HHS K23 AI 62208NIAID NIH HHS P30 AI042853NIMH NIH HHS K24 MH092242
6 · The paper itself

Abstract

Adherence to antiretroviral medications is usually expressed in terms of the proportion of doses taken. However, the timing of doses taken may also be an important dimension to overall adherence. Little is known about whether patients who mistime doses are also more likely to skip doses. Using data from the completed Adherence for Life randomized controlled trial, we created visual and statistical models to capture and analyze dose timing data collected longitudinally with electronic drug monitors (EDM). From scatter plots depicting dose time versus calendar date, we identified dominant patterns of dose taking and calculated key features [slope of line over calendar date; residual mean standard error (RMSE)]. Each was assessed for its ability to categorize subjects with 'sub-optimal' (<95 % of doses taken) using area under the receiver operating characteristic (AROC) curve analysis. Sixty eight subjects contributed EDM data, with ~300 to 400 observations/subject. While regression line slopes did not predict 'sub-optimal' adherence (AROC 0.51, 95 % CI 0.26-0.75), the variability in dose timing (RMSE) was strongly predictive (AROC 0.79, 95 % CI 0.62-0.97). Compared with the lowest quartile of RMSE (minimal dose time variability), each successive quartile roughly doubled the odds of 'sub-optimal' adherence (OR 2.1, 95 % CI 1.3-3.4). Patterns of dose timing and mistiming are strongly related to overall adherence behavior. Notably, individuals who skip doses are more likely to mistime doses, with the degree of risk positively correlated with the extent of dose timing variability.

Indexed as

Dose-Response Relationship, DrugDrug MonitoringAdultAnti-HIV AgentsCohort StudiesDrug Administration ScheduleElectronicsFemaleHIV InfectionsHumansMaleMiddle AgedModels, StatisticalReminder SystemsROC CurveSocioeconomic FactorsAnti-HIV AgentsAdherenceDose timingEDMElectronic drug monitorsStatistical methods

Identifiers

PMID25893658
PMCPMC4938894
OpenAlexW2073021185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.